Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips After almost 12 months of underperformance, Lixte Biotechnology (NASDAQ: LIXT ) has skyrocketed by 200% in today’s trade. As an overview, Lixte is a clinical-stage biotechnology company. The massive rally in LI...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today, many of the top trending stocks are part of two distinct categories. Big news out of the pharmaceutical sector has several microcap biotech stocks in the green. Last week, Sunshine Biopharma (NASDAQ: SBFM ...
LIXTE Biotechnology Holdings (LIXT +86.4%) stock price rockets as it entered into definitive agreements for the purchase and sale of 2.9M shares, at a purchase price of $2/share, in a registered direct offering. The gross proceeds of ~$5.8M will be used for working ca...
PASADENA, CA, April 12, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has entered into definitive agreements for the purc...
Gainers: Lixte Biotechnology Holdings (LIXT) +205%. PolarityTE (PTE) +96%. Biodesix (BDSX) +29%. MiNK Therapeutics (INKT) +27%. Enservco (ENSV) +25%. Actinium Pharmaceuticals (ATNM) +21%. Compass Therapeutics (CMPX) +21%. Sunshine Biopharma (SBFM) +22%. Singularity Future Technology (SGLY) +2...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Lixte Biotechnology (NASDAQ: LIXT ) stock is rocketing higher on Tuesday after the pharmaceutical company revealed pre-clinical results for one of its treatments. Source: CI Photos / Shutterstock.com This data...
LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) reports that Professor René Bernards, Netherlands Cancer Institute, Amsterdam has presented new data from promising drug combinations of LIXTE’s lead clinical cancer compound, LB-100 at the Annual Meeting of America...
Gainers: Lixte Biotechnology LIXT +263%. BioCardia BCDA +29%. Biodesix BDSX +27%. Aeglea BioTherapeutics AGLE +16%. Actinium Pharmaceuticals ATNM +14%. Losers: Hoth Therapeutics HOTH -30%. Altamira Therapeutics CYTO -29%. Myovant Sciences (MYO...
Nano-cap stock, Lixte Biotechnology (NASDAQ:LIXT) has climbed ~142% in the pre-market on Tuesday after announcing new evidence to support the anti-cancer properties of the company’s lead therapeutic compound, LB-100. The data were based on initial studies conducted by the dev...
3 Penny Stocks to Watch Ahead of the Stock Market Open Today After a less than stellar day of trading penny stocks on April 11th, investors have high hopes for today. In the past few weeks, anyone who has traded either penny stocks or blue chips is no stranger to volatility. [...
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Company Name:
LIXT Stock Symbol:
OTCMKTS Market:
Lixte Biotechnology Holdings Inc. Website:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...